Limits...
Regression of follicular lymphoma with Devil's Claw: coincidence or causation?

Wilson KS - Curr Oncol (2009)

Bottom Line: Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years.Inhibition of COX-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment.The timing of the response suggests a positive effect.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Vancouver Island Centre, Victoria, British Columbia. kwilson@bccancer.bc.ca

ABSTRACT

Background: Cancer patients frequently use alternative therapies. Two follicular lymphoma patients who had objective tumour regression after taking Devil's Claw without cytotoxic therapy are reported here.

Methods and results: Patient 1 presented with coexistent immunoglobulin G plasma cell dyscrasia and stage iiia lymphoma (nodes 5 cm in diameter). Computed tomography scan 10 months later showed partial regression. On enquiry, it was learned that the patient was taking Devil's Claw and Essiac (Essiac Products Services, Pompano Beach, FL, U.S.A.). This patient later developed overt myeloma, at which time he stopped the herbal supplements and underwent high-dose chemotherapy and stem cell transplantation, since which no lymphoma progression has occurred. Patient 2 presented with stage IIIA lymphoma (nodes 2.5 cm in diameter). He learned of patient 1 through our lymphoma patient support group and started Devil's Claw. Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years.

Discussion and conclusions: Devil's Claw tuberous root has anti-inflammatory properties, probably through suppression of cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase expression. There are no prior reports of anticancer activity. Inhibition of COX-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment. However, spontaneous regression in lymphoma has been reported in 16% of patients in one series, of whom none were on herbal medications or COX-2 inhibitors. The key issue in both these patients is whether disease regression was "spontaneous" or causally related to therapy with Devil's Claw. The timing of the response suggests a positive effect. Further investigation is warranted, preferably with a COX-2 inhibitor of known purity.

No MeSH data available.


Related in: MedlinePlus

Patient 1: abdominal computed tomography scans showing regression of retroperitoneal adenopathy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2722058&req=5

f1-co16-4-67: Patient 1: abdominal computed tomography scans showing regression of retroperitoneal adenopathy.

Mentions: Because this patient was asymptomatic, observation was recommended, with review in 3 months. Of his own volition, he started taking supplements of Devil’s Claw extract 500 mg daily and Essiac (Essiac Products Services, Pompano Beach, FL, U.S.A.) from a health food store. When assessed in July 2000, the left neck mass was no longer palpable. Follow-up ct scan in November 2000 showed a marked reduction in the size of the retroperitoneal nodes (Figure 1). He developed overt myeloma in August 2001, at which time he stopped the herbal supplements and received dexamethasone, followed by high-dose melphalan, cyclophosphamide, and autologous peripheral blood stem-cell rescue. His myeloma responded, but there has since been evidence of paraprotein progression. No clinical progression of his cervical adenopathy has been observed through September 2008, probably as a result of the high-dose chemotherapy. He has not had a further ct scan because of contrast risk in patients with myeloma proteins.


Regression of follicular lymphoma with Devil's Claw: coincidence or causation?

Wilson KS - Curr Oncol (2009)

Patient 1: abdominal computed tomography scans showing regression of retroperitoneal adenopathy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2722058&req=5

f1-co16-4-67: Patient 1: abdominal computed tomography scans showing regression of retroperitoneal adenopathy.
Mentions: Because this patient was asymptomatic, observation was recommended, with review in 3 months. Of his own volition, he started taking supplements of Devil’s Claw extract 500 mg daily and Essiac (Essiac Products Services, Pompano Beach, FL, U.S.A.) from a health food store. When assessed in July 2000, the left neck mass was no longer palpable. Follow-up ct scan in November 2000 showed a marked reduction in the size of the retroperitoneal nodes (Figure 1). He developed overt myeloma in August 2001, at which time he stopped the herbal supplements and received dexamethasone, followed by high-dose melphalan, cyclophosphamide, and autologous peripheral blood stem-cell rescue. His myeloma responded, but there has since been evidence of paraprotein progression. No clinical progression of his cervical adenopathy has been observed through September 2008, probably as a result of the high-dose chemotherapy. He has not had a further ct scan because of contrast risk in patients with myeloma proteins.

Bottom Line: Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years.Inhibition of COX-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment.The timing of the response suggests a positive effect.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Vancouver Island Centre, Victoria, British Columbia. kwilson@bccancer.bc.ca

ABSTRACT

Background: Cancer patients frequently use alternative therapies. Two follicular lymphoma patients who had objective tumour regression after taking Devil's Claw without cytotoxic therapy are reported here.

Methods and results: Patient 1 presented with coexistent immunoglobulin G plasma cell dyscrasia and stage iiia lymphoma (nodes 5 cm in diameter). Computed tomography scan 10 months later showed partial regression. On enquiry, it was learned that the patient was taking Devil's Claw and Essiac (Essiac Products Services, Pompano Beach, FL, U.S.A.). This patient later developed overt myeloma, at which time he stopped the herbal supplements and underwent high-dose chemotherapy and stem cell transplantation, since which no lymphoma progression has occurred. Patient 2 presented with stage IIIA lymphoma (nodes 2.5 cm in diameter). He learned of patient 1 through our lymphoma patient support group and started Devil's Claw. Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years.

Discussion and conclusions: Devil's Claw tuberous root has anti-inflammatory properties, probably through suppression of cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase expression. There are no prior reports of anticancer activity. Inhibition of COX-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment. However, spontaneous regression in lymphoma has been reported in 16% of patients in one series, of whom none were on herbal medications or COX-2 inhibitors. The key issue in both these patients is whether disease regression was "spontaneous" or causally related to therapy with Devil's Claw. The timing of the response suggests a positive effect. Further investigation is warranted, preferably with a COX-2 inhibitor of known purity.

No MeSH data available.


Related in: MedlinePlus